Business
Jaguar Health Appoints Ian Wendt Vice President, Commercial Strategy
Reminder: Company to Host Investor Call Nov. 14th at 9 a.m. Eastern Regarding Interim Analysis of HALT-D Study of Mytesi (Crofelemer) for Prevention of
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Reminder: Company to Host Investor Call Nov. 14th at 9 a.m. Eastern Regarding Interim Analysis of HALT-D Study of Mytesi (Crofelemer) for Prevention of Diarrhea in Breast Cancer Patients, Q3 Financials & Business UpdatesSAN FRANCISCO, CA / ACCESSWIRE / November 13, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) (\"Jaguar\" or the \"Company\") announced today that it has named Ian Wendt, an executive who has held commercial leadership roles across sales, marketing and operations at some of the largest brands in the pharmaceutical industry during his 25 years in the sector, to the role of vice president, commercial strategy for both Jaguar and the Company's wholly-owned subsidiary, Napo Pharmaceuticals, Inc.\"We're very happy to have appointed Ian to this key role,\" Lisa Conte, Jaguar's president and CEO, stated. \"We believe his broad commercial leadership expertise in the pharmaceutical industry, and in the HIV sector, will play a significant role as we continue to focus on enhancing patient and market access to Mytesi® (crofelemer) for its current FDA-approved indication. Additionally, we expect him to play a pivotal role in driving commercial efforts in the cancer sector if crofelemer receives approval for our primary target follow-on indication, the symptomatic relief of cancer therapy-related diarrhea.\"Prior to joining Jaguar, Wendt was at Gilead Sciences in a variety of field leadership and marketing roles in the HIV and hepatitis C therapeutic areas. Most recently, he led strategy and tactical development for a national team focused on policy and protocol development within key HIV treatment and prevention accounts, capacity building, and direct patient education. Wendt was also responsible for Gilead's efforts to increase hepatitis C virus screening and treatment among non-specialist health care practitioners in support of Gilead's market development efforts for a $10 billion brand franchise. Before Gilead, Wendt was at Boehringer Ingelheim, where he led HIV and oncology sales teams across the US, and led commercial operations at Roxane Laboratories, which included sales operations, analytics, incentive compensation, and training. He received a BSc from Acadia University and an MBA from Dalhousie University in Nova Scotia.\"I firmly believe in Jaguar's mission to continue driving commercial growth of Mytesi (crofelemer) for i...